DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
CEMDISIRAN
2
Oligonucleotide
Investigational
Unknown
Unknown
Atypical Hemolytic Uremic Syndrome; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal
Complement C5 mRNA RNAi inhibitor
CEMDISIRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
S66Z65E10T
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LB-100
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Oligodendroglioma
Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor
LB-100
×
Maximum Phase:
2
First Approval:
None
UNII:
0C1JUU9S0L
Molecule Type:
Small molecule
Molecular Formula:
C13H20N2O4
Molecular Weight:
268.31
AlogP:
-0.36
PSA:
70.08
HBD:
1.0
HBA:
#RotB:
2.0
Source:
SODIUM TUNGSTATE
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Unknown
SODIUM TUNGSTATE
×
Maximum Phase:
2
First Approval:
None
UNII:
64LRH4405G
Molecule Type:
Small molecule
Molecular Formula:
Na2O4W
Molecular Weight:
293.82
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
INDIRUBIN
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
INDIRUBIN
×
Maximum Phase:
2
First Approval:
None
UNII:
V86L8P74GI
Molecule Type:
Small molecule
Molecular Formula:
C16H10N2O2
Molecular Weight:
262.27
AlogP:
2.66
PSA:
58.2
HBD:
2.0
HBA:
#RotB:
0.0
Source:
SUVODIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Muscular Dystrophy, Duchenne
Dystrophin pre-mRNA positive modulator
SUVODIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
IBX8A21EH6
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
METHYLSAMIDORPHAN
2
Small molecule
Investigational
Unknown
Unknown
Constipation
Mu opioid receptor antagonist
METHYLSAMIDORPHAN
×
Maximum Phase:
2
First Approval:
None
UNII:
8347HC35J6
Molecule Type:
Small molecule
Molecular Formula:
C22H29N2O4+
Molecular Weight:
385.48
AlogP:
1.4
PSA:
100.62
HBD:
3.0
HBA:
#RotB:
3.0
Source:
DIPHTHERIA TOXOID
2
Unknown
Investigational
Unknown
Unknown
Brain Neoplasms; Glioblastoma; Leukemia, Lymphocytic, Chronic, B-Cell; Meningitis; Meningococcal Infections; Severe Dengue
Unknown
DIPHTHERIA TOXOID
×
Maximum Phase:
2
First Approval:
None
UNII:
IRH51QN26H
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLODANRIGAN
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Neuralgia, Postherpetic
Angiotensin II type 2 (AT-2) receptor antagonist
OLODANRIGAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P0FN522VTO
Molecule Type:
Small molecule
Molecular Formula:
C32H29NO5
Molecular Weight:
507.59
AlogP:
5.44
PSA:
76.07
HBD:
1.0
HBA:
#RotB:
8.0
Source:
SRX246
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Huntington Disease; Mood Disorders; Stress Disorders, Post-Traumatic
Vasopressin V1a receptor antagonist
SRX246
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C43H48F3N5O5
Molecular Weight:
771.88
AlogP:
6.6
PSA:
102.5
HBD:
1.0
HBA:
#RotB:
11.0
Source:
EPI-589
2
Unknown
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Parkinson Disease
Unknown
EPI-589
×
Maximum Phase:
2
First Approval:
None
UNII:
I4ZSB1Q2DU
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TETRAHYDROCANNABIVARIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
TETRAHYDROCANNABIVARIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I5YE3I47D8
Molecule Type:
Small molecule
Molecular Formula:
C19H26O2
Molecular Weight:
286.42
AlogP:
4.96
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
2.0
Source:
MB07811
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Hyperlipidemias; Non-alcoholic Fatty Liver Disease
Thyroid hormone receptor beta-1 agonist
MB07811
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z11398FNQ
Molecule Type:
Small molecule
Molecular Formula:
C28H32ClO5P
Molecular Weight:
514.99
AlogP:
8.08
PSA:
64.99
HBD:
1.0
HBA:
#RotB:
7.0
Source:
CANNABIDIOL ACID
2
Small molecule
Investigational
Unknown
Unknown
Hallux Valgus
Unknown
CANNABIDIOL ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
FJX8O3OJCD
Molecule Type:
Small molecule
Molecular Formula:
C22H30O4
Molecular Weight:
358.48
AlogP:
5.54
PSA:
77.76
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DAROTROPIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Muscarinic acetylcholine receptor antagonist
DAROTROPIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2W2V1U785A
Molecule Type:
Small molecule
Molecular Formula:
C24H29BrN2
Molecular Weight:
425.41
AlogP:
4.9
PSA:
23.79
HBD:
0.0
HBA:
#RotB:
4.0
Source:
EPALRESTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Aldose reductase inhibitor
EPALRESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
424DV0807X
Molecule Type:
Small molecule
Molecular Formula:
C15H13NO3S2
Molecular Weight:
319.41
AlogP:
2.92
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GUSPERIMUS
2
Small molecule
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Immune System Diseases
Unknown
GUSPERIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
UJ0ZJ76DO9
Molecule Type:
Small molecule
Molecular Formula:
C17H37N7O3
Molecular Weight:
387.53
AlogP:
-1.31
PSA:
178.38
HBD:
8.0
HBA:
#RotB:
17.0
Source:
FOLLICLE STIMULATING HORMONE (FSH)
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
FOLLICLE STIMULATING HORMONE (FSH)
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENOXOLONE
2
Small molecule
Investigational
Unknown
Unknown
Skin Ulcer
Unknown
ENOXOLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
P540XA09DR
Molecule Type:
Small molecule
Molecular Formula:
C30H46O4
Molecular Weight:
470.69
AlogP:
6.41
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
1.0
Source:
COSITECAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
COSITECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
24R60NVC41
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O4Si
Molecular Weight:
448.6
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DINALBUPHINE SEBACATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DINALBUPHINE SEBACATE
×
Maximum Phase:
2
First Approval:
None
UNII:
464OXX39Y6
Molecule Type:
Small molecule
Molecular Formula:
C52H68N2O10
Molecular Weight:
881.12
AlogP:
5.95
PSA:
158.46
HBD:
4.0
HBA:
#RotB:
15.0
Source:
PLAGUE VACCINE
2
Unknown
Investigational
Unknown
Unknown
Plague
Unknown
PLAGUE VACCINE
×
Maximum Phase:
2
First Approval:
None
UNII:
G10832YT0L
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ND0801
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
ND0801
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLESATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor inhibitor
GLESATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
7Q29OXD98N
Molecule Type:
Small molecule
Molecular Formula:
C31H27F2N5O3S2
Molecular Weight:
619.72
AlogP:
6.22
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
11.0
Source:
TALACTOFERRIN ALFA
2
Protein
Investigational
Unknown
Unknown
Infections; Sepsis; Carcinoma, Non-Small-Cell Lung
Unknown
TALACTOFERRIN ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
7A055A9QRR
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MILVETEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
MILVETEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
LGY1VQ9622
Molecule Type:
Small molecule
Molecular Formula:
C25H29N3O4
Molecular Weight:
435.52
AlogP:
2.97
PSA:
113.85
HBD:
6.0
HBA:
#RotB:
12.0
Source:
EMICERFONT
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Phobia, Social
Corticotropin releasing factor receptor 1 antagonist
EMICERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
OJ8EG4264P
Molecule Type:
Small molecule
Molecular Formula:
C22H24N6O2
Molecular Weight:
404.47
AlogP:
3.12
PSA:
75.52
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SODIUM NITRATE
2
Small molecule
Investigational
Unknown
Unknown
Cardiomyopathy, Hypertrophic; Ischemia; Angina, Stable; Asthma; Coronary Disease; Muscular Dystrophy, Duchenne
Unknown
SODIUM NITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8M4L3H2ZVZ
Molecule Type:
Small molecule
Molecular Formula:
NNaO3
Molecular Weight:
84.99
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GSK2269557
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK2269557
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ISUZINAXIB HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
ISUZINAXIB HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C17H18ClN3O
Molecular Weight:
315.8
AlogP:
3.59
PSA:
50.94
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ZATOLMILAST
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Fragile X Syndrome
Phosphodiesterase 4D inhibitor
ZATOLMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
G786V328X6
Molecule Type:
Small molecule
Molecular Formula:
C21H15ClF3NO2
Molecular Weight:
405.8
AlogP:
5.64
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
5.0
Source:
LANICEMINE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major
Glutamate [NMDA] receptor blocker
LANICEMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9TMU325RK3
Molecule Type:
Small molecule
Molecular Formula:
C13H14N2
Molecular Weight:
198.27
AlogP:
2.32
PSA:
38.91
HBD:
1.0
HBA:
#RotB:
3.0
Source:
FOXY-5
2
Protein
Investigational
Unknown
Unknown
Colonic Neoplasms
Unknown
FOXY-5
×
Maximum Phase:
2
First Approval:
None
UNII:
CBZ9UL0ARB
Molecule Type:
Protein
Molecular Formula:
C26H42N6O12S2
Molecular Weight:
694.79
AlogP:
-2.69
PSA:
286.5
HBD:
10.0
HBA:
#RotB:
24.0
Source:
CDX-3379
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Carcinoma, Squamous Cell
Receptor tyrosine-protein kinase erbB-3 inhibitor
CDX-3379
×
Maximum Phase:
2
First Approval:
None
UNII:
00X6I56YXR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HT-0712
2
Small molecule
Investigational
Unknown
Unknown
Memory Disorders; Rhinitis, Allergic, Seasonal
Phosphodiesterase 4 inhibitor
HT-0712
×
Maximum Phase:
2
First Approval:
None
UNII:
2O43FXG9IG
Molecule Type:
Small molecule
Molecular Formula:
C25H31NO3
Molecular Weight:
393.53
AlogP:
4.79
PSA:
47.56
HBD:
1.0
HBA:
#RotB:
6.0
Source:
OBI-3424
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Biphenotypic, Acute
DNA cross-linking agent
OBI-3424
×
Maximum Phase:
2
First Approval:
None
UNII:
X6SH5T8H76
Molecule Type:
Small molecule
Molecular Formula:
C21H25N4O6P
Molecular Weight:
460.43
AlogP:
3.91
PSA:
105.0
HBD:
0.0
HBA:
#RotB:
9.0
Source:
1
2
…
171
172
173
174
175
176
177
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA